Purespring Therapeutics

Purespring, which commenced operations in November 2020 with a funding of £45 million from Syncona Ltd, is the pioneering organization focusing directly on the podocyte, a specialized kidney cell involved in numerous kidney ailments, through AAV gene therapy. This strategy is founded on the research of Professor Moin Saleem, who is the Professor of Paediatric Renal Medicine at the University of Bristol, overseeing a globally renowned team investigating glomerular diseases.